Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting

Table 2

Clinical and economic outcomes of base-case patients.

Strategies	Tamoxifen strategy	AI 5-year strategy	AI switch strategy
Cost (CNY ¥)	13,613	28,797	20,061
QALYs	10.44	10.84	10.71
Life years	18.34	19.17	18.91
Cumulative probabilities of clinical events
Recurrence of breast cancer	57.63%	47.25%	49.36%
Endometrial cancer	1.97%	0.70%	0.88%
ICER (CNY ¥/QALY, AI 5-year versus Tamoxifen strategy)	NA	38,092	NA
ICER (CNY ¥/QALY, AI 5-year versus AI switch strategy)	NA	68,233	NA

AI: aromatase inhibitor; NA: not applicable.